Chronic myeloid leukemia (CML) and acute myeloid leukemia (AML)

1 acute myeloid leukemia (Huh et al., 2016), 1 chronic myeloid leukemia (Barbouti et al., 2002) and the present patient diagnosed with T-ALL after 2 years of lentiviral hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome (Zamecnikova, unpublished data). In addition, there was an acute myelomonocytic leukemia (AML-M4) patient with der(17)t(17;17)(p13;q2?1) breakpoints (Larson et al., 1986).

Only 4 cases, to date, 3 male patients, aged 60, 76 and years and the present 14 years old female patient with Wiskott-Aldrich syndrome.

Presents as 1 normal chromosome 17 and a der(17)t(17;17) chromosome.

Sole anomaly in the present patient; found in association with +6 and 15-100dmin in AML, as an additional anomaly to -Y, t(9;22)(q34;q11) in CML and to inv(16)(p13q22),+22 in CC: TXT: AML-M4 ID: 1506>.

The unbalanced der(17)t(17;17)(p13;q12-21) has been found mainly as an additional aberration to known primary anomalies, therefore it is probably involved in disease evolution. The formation of the unbalanced der(17)t(17;17)(p13;q12-21) results in partial trisomy of the long arm of chromosome 17 leading to trisomies of genes located on 17q. Potential candidate genes on 17q include RARA, NF1, CSF3 (G-CSF), MPO, ERBB2 and miRNAs. Extra copies of these genes may lead to alterations of gene expression that may play roles during disease development or progression.